By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Hybrigenics SA 

180 Avenue Daumesnil

Paris    F-75012  France
Phone: 33-1-70-91-29-00 Fax: 33-1-70-91-29-49



Company News
Hybrigenics’ Inecalcitol Gets Orphan Drug Designation For The Treatment Of Acute Myeloid Leukemia In The United States 8/12/2015 9:21:41 AM
Hybrigenics Starts Phase II Clinical Trial of Inecalcitol in Chronic Lymphocytic Leukemia 9/11/2012 11:00:28 AM
Bryan, Garnier & Co Initiates Coverage of Hybrigenics with a Target Price of €2.6 3/29/2012 6:56:24 AM
Hybrigenics' Specific Inhibitor of Ubiquitin-Specific Protease 7 (USP7) is Cytotoxic for Chronic Lymphocytic Leukaemia (CLL) Cells in Vitro 10/28/2011 10:33:53 AM
Hybrigenics 2011 First-Half Results 10/18/2011 11:02:59 AM
Hybrigenics and Servier Enter into a License and Research Collaboration Agreement in Oncology and Other Therapeutic Fields 10/10/2011 9:49:14 AM
Hybrigenics Appoints Dr Alain Munoz to its Board of Directors 10/5/2011 10:55:57 AM
Hybrigenics Gets Approval and Funding for a Phase II Clinical Trial of Inecalcitol in Psoriasis 9/6/2011 11:27:12 AM
Hybrigenics Maintains Stable EUR Two Million Revenues in First Half of 2011 8/23/2011 10:00:15 AM
Hybrigenics' Inecalcitol Inhibits the Growth of Human Hormone-Dependent Prostate Cancer Cells in Vitro and in Vivo 7/12/2011 9:23:23 AM